129 related articles for article (PubMed ID: 26421870)
1. Correlation of cadherin-17 protein expression with clinicopathological features and prognosis of patients with sporadic gastric cancer.
Meng W; Gu T; Gao LM; Zong ZG; Meng L; Fu ZZ; Guo L
Braz J Med Biol Res; 2015 Dec; 48(12):1077-86. PubMed ID: 26421870
[TBL] [Abstract][Full Text] [Related]
2. A clinicopathological study on the expression of cadherin-17 and caudal-related homeobox transcription factor (CDX2) in human gastric carcinoma.
Ge J; Chen Z; Wu S; Yuan W; Hu B; Chen Z
Clin Oncol (R Coll Radiol); 2008 May; 20(4):275-83. PubMed ID: 18353622
[TBL] [Abstract][Full Text] [Related]
3. The predictive effect of cadherin-17 on lymph node micrometastasis in pN0 gastric cancer.
Wang J; Yu JC; Kang WM; Wang WZ; Liu YQ; Gu P
Ann Surg Oncol; 2012 May; 19(5):1529-34. PubMed ID: 22009269
[TBL] [Abstract][Full Text] [Related]
4. Association between cadherin-17 expression and pathological characteristics of gastric cancer: a meta-analysis.
Long ZW; Zhou ML; Fu JW; Chu XQ; Wang YN
World J Gastroenterol; 2015 Mar; 21(12):3694-705. PubMed ID: 25834338
[TBL] [Abstract][Full Text] [Related]
5. Cadherin-17 induces tumorigenesis and lymphatic metastasis in gastric cancer through activation of NFκB signaling pathway.
Wang J; Kang WM; Yu JC; Liu YQ; Meng QB; Cao ZJ
Cancer Biol Ther; 2013 Mar; 14(3):262-70. PubMed ID: 23298905
[TBL] [Abstract][Full Text] [Related]
6. CDH17 alters MMP-2 expression via canonical NF-κB signalling in human gastric cancer.
Jiang XJ; Lin J; Cai QH; Zhao JF; Zhang HJ
Gene; 2019 Jan; 682():92-100. PubMed ID: 29783070
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological significant and prognostic influence of cadherin-17 expression in gastric cancer.
Ito R; Oue N; Yoshida K; Kunimitsu K; Nakayama H; Nakachi K; Yasui W
Virchows Arch; 2005 Oct; 447(4):717-22. PubMed ID: 16044349
[TBL] [Abstract][Full Text] [Related]
8. Targeting CDH17 suppresses tumor progression in gastric cancer by downregulating Wnt/β-catenin signaling.
Qiu HB; Zhang LY; Ren C; Zeng ZL; Wu WJ; Luo HY; Zhou ZW; Xu RH
PLoS One; 2013; 8(3):e56959. PubMed ID: 23554857
[TBL] [Abstract][Full Text] [Related]
9. An immunohistochemical study of E-cadherin expression with correlations to clinicopathological features in gastric cancer.
Shun CT; Wu MS; Lin JT; Wang HP; Houng RL; Lee WJ; Wang TH; Chuang SM
Hepatogastroenterology; 1998; 45(22):944-9. PubMed ID: 9755986
[TBL] [Abstract][Full Text] [Related]
10. Lentiviral-mediated miRNA against liver-intestine cadherin suppresses tumor growth and invasiveness of human gastric cancer.
Liu QS; Zhang J; Liu M; Dong WG
Cancer Sci; 2010 Aug; 101(8):1807-12. PubMed ID: 20500517
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor receptor 4 protein expression and clinicopathological features in gastric cancer.
Chen H; Shen DP; Zhang ZZ; Liu JH; Shen YY; Ni XZ
World J Gastroenterol; 2015 Feb; 21(6):1838-44. PubMed ID: 25684949
[TBL] [Abstract][Full Text] [Related]
12. Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma.
Li Y; Chen CQ; He YL; Cai SR; Yang DJ; He WL; Xu JB; Zan WH
J Surg Oncol; 2012 Sep; 106(3):304-10. PubMed ID: 22231933
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological and prognostic significance of the RUNX3 expression in gastric cancer: a systematic review and meta-analysis.
Liu B; Han Y; Jiang L; Jiang D; Li W; Zhang T; Zu G; Zhang X
Int J Surg; 2018 May; 53():122-128. PubMed ID: 29578091
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of E-cadherin in gastric cancer: a meta-analysis.
Xing X; Tang YB; Yuan G; Wang Y; Wang J; Yang Y; Chen M
Int J Cancer; 2013 Jun; 132(11):2589-96. PubMed ID: 23169395
[TBL] [Abstract][Full Text] [Related]
15. Targeting cadherin-17 inactivates Ras/Raf/MEK/ERK signaling and inhibits cell proliferation in gastric cancer.
Lin Z; Zhang C; Zhang M; Xu D; Fang Y; Zhou Z; Chen X; Qin N; Zhang X
PLoS One; 2014; 9(1):e85296. PubMed ID: 24465527
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and clinical significance of VEGFR-3 in gastric cancer: A meta-analysis.
Ge H; Yan Y; Guo L; He X; Yang X
Clin Chim Acta; 2017 Nov; 474():114-119. PubMed ID: 28939099
[TBL] [Abstract][Full Text] [Related]
17. CDX2 co-localizes with liver-intestine cadherin in intestinal metaplasia and adenocarcinoma of the stomach.
Ko S; Chu KM; Luk JM; Wong BW; Yuen ST; Leung SY; Wong J
J Pathol; 2005 Apr; 205(5):615-22. PubMed ID: 15732140
[TBL] [Abstract][Full Text] [Related]
18. [Correlation between the expression of urokinase-type plasminogen activator, E-cadherin and malignancy in gastric cancer].
Itoh H; Yonemura Y; Tsuchihara K; Kawamura T; Nojima N; Kaji M; Fushida S; Nishimura G; Fujimura T; Miwa K
Gan To Kagaku Ryoho; 1995 Jun; 22 Suppl 2():124-9. PubMed ID: 7611774
[TBL] [Abstract][Full Text] [Related]
19.
Fujiwara K; Tsuji AB; Sudo H; Sugyo A; Akiba H; Iwanari H; Kusano-Arai O; Tsumoto K; Momose T; Hamakubo T; Higashi T
Ann Nucl Med; 2020 Jan; 34(1):13-23. PubMed ID: 31605356
[TBL] [Abstract][Full Text] [Related]
20. Abnormal expression of E-cadherin and beta-catenin may be a molecular marker of submucosal invasion and lymph node metastasis in early gastric cancer.
Tanaka M; Kitajima Y; Edakuni G; Sato S; Miyazaki K
Br J Surg; 2002 Feb; 89(2):236-44. PubMed ID: 11856141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
